Yizhiying Technology Secures Tens of Millions RMB in Pre-A Funding Round with Yiran Capital as Exclusive Financial Advisor

On September 30, 2020, VCBeat learned that Beijing Yizhiying Technology Co., Ltd., a high-tech enterprise focused on AI-driven cancer treatment, officially announced the completion of its Pre-A financing round amounting to tens of millions of RMB. The round was jointly invested by Lepu Medical, Guiyang Venture Capital, and Rongtuo Capital, with Yiran Capital serving as the exclusive financial advisor for this financing round.

Beijing Yizhiying Technology Co., Ltd. is an innovative company in the field of artificial intelligence for healthcare. Leveraging its independently developed core technologies in deep learning and medical image analysis, it performs intelligent analysis of big data from medical imaging. The company has developed and deployed intelligent target delineation products and intelligent surgical planning and navigation products that cover major cancer types throughout the body.

Lepu Medical was founded in 1999 and is one of the earliest enterprises in China engaged in the research, development, and manufacturing of cardiovascular interventional medical devices. It is the sole National Engineering Research Center for Cardiac Disease Implantable and Interventional Diagnostic and Therapeutic Devices and Equipment authorized by the Ministry of Science and Technology of China. In 2009, it became one of the first batch of companies listed on the ChiNext board. Lepu Medical is among the few domestic enterprises in the high-end medical device sector capable of competing strongly with international products.

Guiyang Venture Capital Co., Ltd. is a venture capital investment enterprise approved and established by the Guiyang Municipal People's Government. It manages 11 funds with total assets under management exceeding RMB 6 billion, including government guidance funds and mixed-ownership venture capital funds. As a regionalized and specialized VC+FOF fund investment management institution, its investment scope covers pharmaceuticals and healthcare, big data (electronic information/internet), military-civilian integration, and other sectors.

Rongtuo Capital Management Co., Ltd. is a market-oriented investment institution with life and health as one of its core investment sectors. Its investment scope covers innovative drugs, medical devices, and novel therapies with clinical value, with assets under management exceeding RMB 1 billion.

Yiran Capital was established in 2020. The team specializes in providing comprehensive, in-depth financing services to high-quality healthcare enterprises in the fields of innovative drugs, medical devices (IVD), and healthcare services. With a precise grasp of industry trends, the firm possesses extensive experience in project capital operations.